The Biden administration on Thursday asserted its authority to seize the patents of certain costly medications in a new push to slash high drug prices and promote more pharmaceutical competition.
The administration unveiled a framework outlining the factors federal agencies should consider in deciding whether to use a controversial policy, known as march-in rights, to break the patents of drugs that were developed with federal funds but are not widely accessible to the public. For the first time, officials can now factor in a medication’s price — a change that could have big implications for drugmakers depending on how the government uses the powers.
“When drug companies won’t sell taxpayer-funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard said during a call with reporters Wednesday.
I wish media would give credit to the organization leaders responsible for these types of moves rather than crediting a homogeneous “Biden administration.” The fact is that the administration does deserve credit for employing a number of “progressive” (read: competent) administrators, but those departments compose a progressive wing of the administration that is not on par with some of the overall administration’s more centrist leanings.
-- Cory Doctorow
You know, I never really thought about this, you make a good point.
Also, I notice so many people mentioning Cory Doctorow lately, what’s up with that? His oddly spelled lay name is even in my phone’s autocorrect! All small hints of a certain fascination with him.